Home > News Center
 
Contact Us
Shanghai BravoBio Co., Ltd.
Add:Suite 14E, Building #5, Haifu Garden, 1365 Dongfang Road, Lujiazui Financial and Trade Zone, Shanghai 200127, China
Tel: +86 21 2025 5516
Fax: +86 21 2025 5517
Email: bd@bravobio.com
News Center
 
EU approved Merck's Gardasil 9
Jun. 17, 2015
 
European Commission gave a nod to Merck and Sanofi Pasteur to market Gardasil 9-valent HPV jab in member nations, allowing the companies to engage in pricing and reimbursement negotiations with countries individually.
Gardasil 9 protects against HPV types 31, 33, 45, 52 and 58, as well as types 6, 11, 16 and 18. Analysts predict sales to $525 million by 2018.
 
Hualan's flu vaccine passed WHO prequalification
Jun. 18, 2015
 
Hualan's flu vaccine got WHO prequalification in June 2015, making it the second Chinese-made vaccine ever prequalified by WHO. The first was a vaccine against Japanese encephalitis from CNBG Chengdu Institute, approved in October 2013.
Hualan is the largest flu vaccine manufacturer in China, with the capacity of more than 300 million single-dose vaccines and more than 50 million three-dose vaccine regimens annually.
 
Pfizer acquired GlaxoSmithKline quadrivalent meningitis vaccines for $130M
Jun. 24, 2015
 
Pfizer inked a deal with GSK to buy the latter's quadrivalent meningitis vaccines, Nimenrix and Mencevax, targeting the A, C, Y and W-135 strains, for a total of $130 million. Previously, pfizer has Trumenba targeting meningitis B, as well as NeisVac-C targeting meningitis C and acquired from Baxter in 2014.
 
MERS vaccine candidate enters PhI
Jun. 29, 2015
 
As the MERS infected cases continue to increase in South Korea, scientists at Ludwig Maximilian University of Munich announced their vaccine candidate into clinical trials last week. Only last month, they reported that the candidate showed promising results in a trial on mice, with markedly impaired virus replication and decreased numbers of virus genome in lung tissue.
 
Top 5 vaccines by 2020
Jul. 10, 2015
 
EP estimated that Prevnar,Gardasil,Fluzone,Pentacel,and Pediarix would be the the top 5 best selling vaccines by 2020.
 
WHO, EMA in favor of GSK's malaria vaccine
Jul. 17, 2015
 
Despite of the fact that the efficacy of GSK's investigational malaria vaccine, Mosquirix, wanes over time, WHO and EMA still might approve it by the end of this year as it's the first vaccine against malaria. The price might be about $5 per dose.
 
EMA gave Glaxo's malaria vaccine a green light
Jul. 24, 2015
 
This month, GSK's malaria vaccine got EMA's nod for use in children aged 6 weeks to 17 months outside the European Union, being the first malaria vaccine ever evaluated by regulatory agency. Now, GSK is waiting for WHO's recommendation for the use of Mosquirix in national immunization programs. Besides GSK, MVI scored $156 million from the Gates Foundation and Sanaria recently raised $48.5 million to to work on new types of malaria vaccines.
 
Pfizer's Prevnar sales increased dramatically in Q2
Jul. 30, 2015
 
The world's biggest selling vaccine, Prevnar 13, helped Pfizer notch 44% vaccines growth in Q2 2015, with the sales growing from $1.09 billion in last year's Q2 to $1.58 billion during the same period this year. Thanks to the favorable CDC recommendation for universal use in the 65-and-over age range, the vaccine notched a U.S. sales increase of 87% versus the same period last year.
 
Merck Ebola vaccine showed 100% efficacy in PhIII
Aug. 7, 2015
 
Merck'sEbola vaccine has protected 100% of patients from Ebola infection tested in a novel "ring study", which involved more than 4,000 people in Guinea at risk of infection, with half receiving the vaccine, rVSV-ZEBOV, immediately after exposure to the virus, and half vaccinated after a delay. The immediate group reported no cases of Ebola after 10 days, while the other group reported 16 cases.
Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Next